UF startup Rise Therapeutics announced that it has completed the dose escalation portion of its ongoing Phase 1 clinical trial evaluating R-5780, the Company’s lead immuno-oncology candidate. Having established a recommended dose, the study will now move into its planned dose expansion stage to enroll additional cancer patients at the highest fixed dose.
“Completing dose escalation for R-5780 is a meaningful step in translating our novel immunotherapy approach into a potential option for people fighting cancer,” stated Gary Fanger, President and CEO of Rise Therapeutics.
Read more about Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances To Dose Expansion.
